Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Jindong Xie , Manqing Liu , Xinpei Deng , Yuhui Tang , Shaoquan Zheng , Xueqi Ou , Hailin Tang , Xiaoming Xie , Minqing Wu , Yutian Zou
iMeta ›› 2024, Vol. 3 ›› Issue (1) : 156
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
•Gut microbiota has been acknowledged as key regulators in host-mediated anticancer immune response especially during immunotherapy, and antibiotics-induced dysbiosis often leads to resistance to immunotherapy and poor clinical outcomes. •Although the mechanisms underlying gut microbiota-mediated potentiating efficacy while ameliorating side effects of immunotherapy differs across bacteria genus and immunotherapy types, it’s generally via enhancing anticancer immunity and remodulating the tumor microenvironment. •We reviewed the commensal bacteria profiles associated with responders to immunotherapy in various cancer types, characterized by a high diversity with abundance of specific species, which may help predict patients; sensitivity to immunotherapy before treatment. •Since the causal relationship between individual gut microbiota and response to immunotherapy, we propose gut microbiota act as the future therapeutic target and adjuvant in personalized anticancer regimen, and reviewed the current dilemma and potential strategies to manipulate gut microbiota towards “beneficial bacteria.”
cancer / gut microbiota / immunotherapy / immune-related adverse events / predominant bacteria / precision medicine
2024 The Authors. iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.
/
| 〈 |
|
〉 |
PDF
